Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 23, 2026.

Bacterial Vaginosis: What Do We Currently Know?

Linda Abou Chacra, Florence Fenollar, Khoudia Diop

Frontiers in Cellular and Infection Microbiology · 2022 · Review · CC BY

doi:10.3389/fcimb.2021.672429

Abstract

The vaginal microbiome is a well-defined compartment of the human microbiome. It has unique conditions, characterized by the dominance of one bacterial species, the Lactobacilli. This microbiota manifests itself by a low degree of diversity and by a strong dynamic of change in its composition under the influence of various exogenous and endogenous factors. The increase in diversity may paradoxically be associated with dysbiosis, such as bacterial vaginosis (BV). BV is the result of a disturbance in the vaginal ecosystem; i.e., a sudden replacement of Lactobacilli by anaerobic bacteria such as Gardnerella vaginalis, Atopobium vaginae, Ureaplasma urealyticum, Mycoplasma hominis , and others. It is the most common cause of vaginal discharge in women of childbearing age, approximately 30% of all causes. The etiology of this dysbiosis remains unknown, but its health consequences are significant, including obstetrical complications, increased risk of sexually transmitted infections and urogenital infections. Its diagnosis is based on Amsel’s clinical criteria and/or a gram stain based on the Nugent score. While both of these methods have been widely applied worldwide for approximately three decades, Nugent score are still considered the “gold standard” of BV diagnostic tools. Given the limitations of these tools, methods based on molecular biology have been developed as alternative rational strategies for the diagnosis of BV. The treatment of BV aims at restoring the balance of the vaginal flora to stop the proliferation of harmful microorganisms. Prescription of antibiotics such as metronidazole, clindamycin, etc. is recommended. Faced with the considerable uncertainty about the cause of BV, the high rate of recurrence, the unacceptable treatment options, and clinical management which is often insensitive and inconsistent, research on this topic is intensifying. Knowledge of its composition and its associated variations represents the key element in improving the therapeutic management of patients with the most suitable treatments possible.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

1 Introduction

The vaginal microbial community is complex and dynamic, consisting of a group of bacteria typically characterized by abundant Lactobacilli that evolve during the life of the woman, depending on age, hormonal estrogen levels, sexual practices and the environment. The vaginal microbiota plays a crucial role in women’s health (infection, reproduction…), and that of their fetuses.

BV is a dysbiosis of the vaginal microbiota characterized by a shift from Lactobacilli dominance to that of a mixture of various anaerobic bacteria. It is the most common vaginal disorder worldwide in women of childbearing age. BV is associated with significant adverse healthcare outcomes, including increased susceptibility to sexually transmitted infections, urogenital infections, pelvic inflammatory disease, and an increased risk of abnormal pregnancy. The etiology of BV is still unknown. Standard antibiotic therapy often fails, with an estimated relapse rate of 50% at six months follow-up.

2 Normal Healthy Vaginal Flora

The vaginal ecosystem is colonized from the very first hours of the birth of a female and remains throughout her life until death. Women of childbearing age produce about 1 to 4 mL of vaginal fluid, containing 108 to 109 bacterial cells per mL.

2.1 Composition of Normal Vaginal Flora

The vaginal flora was first described by the German gynecologist Albert Döderlein in 1892, who reported a homogeneous vaginal flora of gram-positive bacilli in healthy women. They were named “Döderlein’s bacilli” and were later identified as members of the Lactobacillus genus by Beijerink in 1901. Under normal conditions, 70-90% of the vaginal bacterial species in healthy premenopausal women are Lactobacilli. As molecular techniques have advanced, our understanding of the diversity and complexity of the vaginal bacterial community has broadened. Among more than 200 Lactobacillus species with standing in the nomenclature, over 20 species have been found in the vaginal flora. Sequencing of the 16 rRNA gene revealed that the vaginal bacterial community, mainly composed of Lactobacilli, is classified into five groups named community state types, namely I, II, III, IV and V. Four of these groups are dominated by Lactobacillus. The first is dominated by L. crispatus, the second by L. gasseri, the third by L. iners, and the fifth by L. jensenii, while the fourth contains a smaller proportion of Lactobacilli but is composed of a polymicrobial mixture of strict and facultative anaerobes (Gardnerella, Atopobium, Mobiluncus, Prevotella…). Although there is always a temporal transition between vaginal bacterial communities ( Figure 1 ).

Thus, many other bacteria are present at lower concentrations in healthy vaginal flora, such as Peptostreptococcus, Bacteroides, Corynebacterium, Streptococcus, and Peptococcus.

The composition of the vaginal microbiota evolves throughout a woman’s lifespan. Various physical and hormonal changes occur in the vagina biotope during these different stages of a woman’s life ( Figure 2 ).

2.2 Variability of Vaginal Flora According to Ethnicity

Vaginal bacterial communities of women of childbearing age may vary between women from different regions, but also between women of different ethnicities living in the same geographical area. In 2011, a study by Ravel et al. characterized the vaginal microbiota of asymptomatic North American women with pyrosequencing, showing that the vaginal flora of Asian and white American women was dominated by Lactobacilli, unlike Hispanic and African-American women, of whom only 60% had a Lactobacillus -dominated vaginal flora. In addition, Caucasian and Asian women tend to have high levels of L. crispatus and lower levels of L. iners compared to African women. In another study using 16S rRNA gene sequencing, Fettweis et al. demonstrated that the vaginal microbiota of European-ancestry women was dominated by Lactobacilli, as opposed to African-American women, who presented a mixed vaginal community containing, among others, Mycoplasma hominis, Aerococcus, L. iners and numerous strict anaerobes, including gram-positive anaerobic cocci, BV-associated bacteria, Sneathia, Prevotella amnii, Megasphaera, Atopobium, and Gardnerella vaginalis. The vaginal pH also differs between racial groups. African-American and Hispanic women had a vaginal pH (4.7 and 5.0, respectively) higher than what is considered the norm (<4.5).

2.3 Role of the Vaginal Microbiota in Women’s Health

The vaginal flora presents one of the most important defense mechanisms for reproductive function and maintaining a healthy environment. The stability of this flora prevents the proliferation of commensal microorganisms and colonization by pathogens, thereby preventing infection. Bacteria form a adhered monolayer on the vaginal mucosa and produce antimicrobial compounds that maintain this health equilibrium, such as hydrogen peroxide (antimicrobial product protecting against deleterious microorganisms), lactic acid (which maintains the normal vaginal pH between 3.5 to 4.5), bacteriocins (antibiotics that inhibit the growth of harmful microorganisms within the vagina), and arginine deaminase enzyme (metabolizes arginine into citrulline and ammonia (NH3), depriving anaerobic pathogens of this amino acid necessary for their growth).

Notably, L. crispatus and L. jensenii may produce hydrogen peroxide, an oxidizing agent, toxic for catalase-negative bacteria and also capable in vitro of inhibiting HIV-1 and herpes simplex virus type 2. The vaginal acids produced can, in the presence of viral RNA, stimulate the maturation of dendritic cells, activation of 17 subclasses of T helper lymphocytes, and the production of protective inflammatory cytokines and interferon-γ.

In addition to the role of Lactobacilli, cervical mucus is mainly composed of mucin, which protects the vaginal mucosa and optimizes its barrier role against microbial colonization. Analyses of the composition of cervical mucus and vaginal secretions have demonstrated the presence of several proteins with antimicrobial activities that act independently of the presence of antibodies, such as lactoferrin, lysosyme, calprotectin [also known as MRP8/MRP14 (“myeloid related protein”)], cathelicidin LL-37.

3.1 Background

Formerly known as non-specific vaginitis, BV is characterized by a change in the vaginal flora composition, with a dramatic depletion of Lactobacilli due to a significant overgrowth of obligate or facultative anaerobes previously a minority in the vagina, such as Gardnerella vaginalis, Atopobium vaginae, Ureaplasma urealyticum, Mycoplasma hominis, Prevotella, Peptoniphilus, Megasphaera, Mobiluncus, and several fastidious and uncultured bacteria, including BV-associated bacteria (BVAB-1 to 3). The factor triggering this overgrowth of anaerobic bacteria is unknown. It is linked to an alkaline vaginal ecosystem due to an increase of vaginal pH following the loss of Lactobacilli protective effects ( Figure 3 ).

The diversity of the vaginal flora in patients with BV was described in 1921 by Schröder. In 1955, Gardner and Dukes claimed that the etiological agent of BV was Haemophilus vaginalis, a gram-negative rod later renamed Gardnerella vaginalis. The bacteria present in the microbiota of BV form a biofilm on the vaginal epithelium and secrete a cytotoxin capable of killing the epithelial cells. In addition, G.vaginalis produce proteolytic enzymes able to degrade proteins and decarboxylases that convert amino acids. Not being degraded, the amine compounds become malodorous (fishy odor: “Whiff test”) thank to an increase of the vaginal pH. Subsequently, cytotoxicity resulting from the combination of organic acids present in the vagina during BV and bacterial polyamines leads to the production of a vaginal discharge caused by the exfoliation of vaginal epithelial cells. Furthermore, this bacterium, cover the vaginal epithelial cells, causing the formation of “clue-cells”, a specific characteristic of BV.

A few years later, G. vaginalis was found in 40% of healthy women, and its role was disputed. Thus, colonization of G. vaginalis does not always promote BV, suggesting that this bacterium alone may be essential but not sufficient for BV development. In addition to G. vaginalis, some anaerobic bacteria are highly associated with BV, indicating that BV is a polymicrobial syndrome, which does not follow Koch’s postulates.

Recent progress in research of BV pathogenesis have determined the existence of 13 different species within the genus Gardnerella. Although these Gardnerella species may be closely linked genetically, only a few of them may be implicated in disease such as BV. Healthy women may be colonized by non-pathogenic Gardnerella species, whereas virulent strains are involved in the development of BV. Advances in technology, particularly next-generation sequencing, have clarified much of this issue. Arguably, all papers dealing with G. vaginalis prior to that of Vaneechoutte et al. are not specifically about G. vaginalis but rather about Gardnerella spp.

Based on a recent prospective study, an updated conceptual model on the pathogenesis of BV was outlined. The potential synergistic relationship between G. vaginalis, P. bivia, A. vaginae was studied. After sexual exposure to virulent strains of G. vaginalis, these strains displace vaginal Lactobacilli and begin to form a BV biofilm on the vaginal epithelium. Subsequently, proteolysis by G. vaginalis occurs which promotes the growth of P. bivia. This bacterium produces an ammonia product which in turn promotes the growth of G. vaginalis and the biofilm develops. These 2 bacteria then produce sialidase that degrades the biofilm and P. bivia may thus degrade the mucin layer of the vaginal epithelium. After the loss of the protective mucus layer, increased adhesion of other BV-associated bacteria, including A. vaginae, to the polymicrobial biofilm will occur. The role of the other bacteria remains unknown. Further research focusing on the complex interactions between bacteria during BV is needed.

3.2 Diagnosis

BV ranges from asymptomatic to an increase in vaginal discharge with or without a fishy odor. The collection of a specimen for diagnosis can be performed using a speculum during the pelvic exam. When there is no reason for a pelvic exam as part of the clinical evaluation, a self-collected vaginal swab may also be provided.

3.2.1 Amsel Criteria and Nugent’s Score

Two main categories of diagnostic strategies for BV exist: the “bedside” method introduced in 1983, mainly based on real-time clinical criteria –”Amsel’s criteria”, and laboratory-based testing developed in 1991, relying on the evaluation of morphotypes on gram staining – “ Nugent’s score”. Amsel’s criteria and Nugent’s score are the most common diagnostic methods used for BV. Furthermore, the World Health Organization (WHO) has considered the Nugent’s score as a gold standard for studies. However, the current recommended best clinical practice for diagnosing BV in women is gram staining microscopy according to the Hay-Ison criteria, as it is easier and faster to use. The Hay-Ison criteria were analogous to the Nugent’s scores. Hay’s grades I, II, and III were similar to Nugent’s scores 0-3, 4-6, and 7-10.

Even if Nugent’s score is considered as a gold standard by the WHO, it has some pitfalls. In fact, intermediate flora is so far an uncharacterized category and is a challenge in the diagnosis of BV. In addition, the identification of morphotypes is subjective and technician-dependent, thus the diagnosis may be influenced by individual skills and experience.

Recently, a study made by Wang et al. provided a proof of concept for a deep learning-based model to quantify Gram staining and, consequently, automated Nugent score classification. Deep learning methods, particularly convolutional neural network (CNN) models, have demonstrated excellent performance in computer vision tasks. This model outperformed human healthcare professionals in terms of accuracy and stability for three diagnostic categories of Nugent scores. The deep learning model may offer translational applications in automating the diagnosis of BV with appropriate supporting hardware.

3.2.2 Molecular Diagnostic Technique

The diagnosis of BV is problematic and challenging because of its intricate polymicrobial features and a wide range of clinical features. In order to overcome these diagnostic problems, alternative diagnostic strategies have been attempted, such as molecular, enzymatic and chromatographic techniques.

A molecular technique used in the diagnosis of BV is specific quantitative real-time PCR (qPCR) test. It is a quantitative, reproducible and reliable molecular biology tool that measures the presence of bacteria presents in BV, such as Atopobium vaginae, BVAB2, Gardnerella vaginalis, Leptotrichia/Sneathia spp., Megasphaera spp., and Mobiluncus spp….. Many studies proposed objective molecular cut-off values from bacterial load to predict BV.

Several commercially molecular diagnostic assays have been reported for the diagnosis of BV in women including the NuSwab R multiplex quantitative PCR, SureSwab BV DNA real-time quantitative assay, BD Max vaginal panel and BV multiplex assay. The quantification of these bacteria therefore makes it possible to establish a precise diagnosis of BV, with a sensitivity ranging from 90.5% to 96.7% and a specificity ranging from 85.8% to 95% compared to Amsel criteria and Nugent score.

Even though these tests have a higher sensitivity and specificity than the currently available diagnostic tools, they are not point-of-care tests and are more expensive. However, Dessai et al. are the first to report on the performance of the BD AffirmTM VPIII test as a POCT in a prenatal population. But the test has been shown to be inadequate as a screening test for vaginal infections in pregnancy.

Finally, POC tests for BV are not available or are simply too expensive to be used routinely. It is therefore mandatory that the development and evaluation of new diagnostic tests include a cost analysis.

3.2.3 Other Emerging Strategies

As the presence of sialidase is currently considered a key indicator of BV in the clinical examination, an enzymatic approach has been developed: The OSOM R BVBlue R test as a POC diagnostic test for BV. It is based on the qualitative detection of a high level of sialidase produced by anaerobic pathogens in vaginal fluid samples. It has been shown to be reliable compared to conventional methods such as Amsel criteria and Nugent score

In addition, a recent study by Liu et al., showed the feasibility of turn-on tetravalent sialic acid-coated tetraphenylethene luminogen (TPE4S) as a powerful diagnostic tool for high-throughput fluorescence-guided diagnosis of BV. This study uses light signal intensity to detect and measure the relative concentration of sialidase in a vaginal sample. All reagents are present in a reagent bead and sample buffer, essentially allowing for a one-step test. The test is highly sensitive and quantitative, with a sensitivity and specificity of 95.40% and 94.94%, respectively, compared to the Amsel method and 92.5% and 91.8% compared to the BVBlue diagnostic results. Notably, this method gives a more accurate classification and quantification of BV severity based on relative fluorescence intensity (I/I0). Thus this test can be a potential tool for diagnosis of BV, and risk assessment of patients with BV based on sialidase activity levels and monitoring of antibiotic therapy.

Another new approach based on immunodetection also targeting sialidase has been developed for the diagnosis of BV. The nanophotonic operating principle of this biodetection method allows a cheaper, faster and simpler analysis than the indirect enzyme-linked immunosorbent assay (ELISA). This nanotechnology has a high sensitivity and specificity (96,29%, respectively). This method offers an original approach to perform a very rapid diagnosis of BV.

3.3 Epidemiology and Risk Factors

BV may appear at any reproductive age (between 15 to 44 years-old). Its prevalence rates vary considerably among the geographic regions of the world, within the same country, and even within the same population, depending on ethnic origin and socioeconomic status. Although its exact prevalence remains difficult to determine, BV occurs between 4-75%, depending on the population studied. Intermediate in the USA (29%), the prevalence of BV is estimated to be low in Europe, with a maximum (> 20%) in Poland and Norway. In Africa, the estimated prevalence tends to be high. However, BV prevalence is lowest in west Africa (6-8% in Burkina Faso, 14.2% in Nigeria) than southern and eastern Africa: 32.5% in Zimbabwe, 37% in Kenya, 38% in Botswana, and 68.3% in Mozambique.

3.3.1 Sexual Practices

Although the absence of a known causal agent makes it difficult to characterize BV as a sexually transmitted infection (STI), it is strongly associated with sexual activities and has some characteristics of a sexually transmitted disease not by microorganism transfer, but by mechanical or chemical interaction such as contact with highly alkaline semen. Overall, BV is diagnosed in post-pubertal women who have never been sexually active, but at a lower prevalence than those who are sexually active. The prevalence varies with the number of sex partners. It has been evaluated at 18.8% for non-sexually active women, 22.4% for women with one lifetime partner and 43.4% and 58% for women having 2-3 lifetime sex partners and those having ≥ 4-lifetime sex partners, respectively.

In this dynamic, sex workers had a higher bacterial vaginal diversity but a much lower abundance of Lactobacillus species than women who are not engaged in sex work. Compared with male partners of healthy women, BV-related bacteria can be found in the penile skin, urethra, spermatozoa, and prostatic fluid microbiota of male partners of women with BV. Furthermore, biofilm fragments have been found in their urine and sperm, suggesting that male partners are a reservoir, and also that heterosexual transmission may occur. Nevertheless, there is no corresponding illness in male partners. Use of condoms by male partners also prevents acquisition and recurrence of BV. Also, since the preputial area of some men hosts BV-associated microorganisms, male circumcision may reduce the risk of BV.

Prevalence rates also depend on the nature of the couple and their sexual practices. In fact, BV prevalence varies between 10-30% in heterosexual women, and is more frequent, 25-50%, in women who have sex with women (WSW). The reasons for this difference in prevalence are not clear, although sexual activities involving the transmission of vaginal fluid increase the risk of BV acquisition. Several studies have indicated that certain sexual behaviors, including non-coital sexual practices such as digital and penile penetration, anal and oral intercourse followed by vaginal penetration, enhance the risk of BV. In WSW, a symptomatic female sexual partner, receptive oral sex, and the use and sharing of unwashed sex toys constitute risk factors for BV. These observations have led some to consider BV as not an infection, but rather a taxonomic change in the vaginal microbiota resulting from translocation of oral or fecal microbiota during non-coital sexual practices.

3.3.2 Other Bacterial Vaginosis Risk Factors

Additionally, genital hygiene can also promote disequilibrium in the vaginal microbiota. One study found that patients who did not wash their vaginal region were more susceptible to BV than those who often washed the vaginal region, a prevalence of 53.9% and 40.2%, respectively. Similarly, the prevalence of BV is higher in patients who do not change their underpants frequently compared to those who change it more frequently (57.6% versus 36.9%). In addition, other sexual sanitary habits, including vaginal douching and washing, as well as cigarette smoking, certain contraceptive methods like disposable intra-uterine devices and stress may also enhance the risk of developing BV.

3.4 Bacterial Vaginosis Complications and Women’s Health

Women with BV are vulnerable: the presence of BV-related bacteria and/or sexually transmissible microorganisms in the BV microbiota can lead to opportunistic infections. During this imbalance, 10-30% of pregnant women with BV give birth prematurely, a preterm delivery often accompanied by perinatal mortality, up to 70% worldwide. During pregnancy, BV increases the risk of preterm labor, late miscarriage, intrauterine fetal death, preterm rupture of the membranes, amniotic fluid infections, chorioamnionitis, post-abortion and postpartum infections in these women.

In non-pregnant women, bacteria involved in BV can initially cause cervicitis, endometritis, salpingitis, and urinary tract infections. After damage of the cervix, bacteria can migrate from the lower to upper genital tract, reaching the uterus and fallopian tubes and causing illnesses such as pelvic inflammatory disease, post-hysterectomy infections, and even cervical cancer or tubal infertility (van; ). Likewise, BV is associated with significantly increased rates of acquiring herpes simplex virus, human immunodeficiency virus, papillomavirus and transmission of the pathogens causing syphilis, chancroid, gonorrhea, trichomoniasis, and chlamydia.

3.5 Treatment and Management of Bacterial Vaginosis

Considering that clinical cure corresponds to the disappearance of all symptoms, the treatment of BV is currently focused on stopping the proliferation of BV-associated microorganisms and restoring the normal vaginal flora. Typically, clinical therapies include the use of antibiotics with broad activity against anaerobic microbes and protozoa: clindamycin and the nitroimidazoles (metronidazole and tinidazole) and/or use of probiotics.

3.5.1 Antibiotic Therapies

The first line of therapy recommended by the World Health Organization (WHO) is 500 mg oral metronidazole twice daily for one week. However, treatment with metronidazole may cause side effects such as gastrointestinal pain, nausea, and vomiting. Other proposed therapeutic regimens include 300 mg oral clindamycin twice daily for one week, 100 mg of intravaginal clindamycin ovule daily for 5 days and an application of 0.75% intravaginal metronidazole gel for 5 days or 2% of intravaginal clindamycin cream at bedtime for one week. However, it should be noted that local application of clindamycin may damage latex-based products such as condoms and may also trigger pseudomembranous colitis.

In addition, the use of tinidazole, a drug similar to metronidazole, has been approved and proposed as an alternative therapy in an oral regimen (either 2 g/day for 2 days or 1g/day for 5 days) if metronidazole and clindamycin are not tolerated.

Some researchers have evaluated the efficacy of other antimicrobial agents, such as azithromycin, secnidazole or ornidazole and rifaximin. Secnidazole has shown activity similar to that of the recommended nitroimidazoles and also spares Lactobacilli, a beneficial characteristic in BV treatment. Even for Rifaximin, it acts on BV by restoring Lactobacilli and increasing lactic acid in patients.

Taken locally or orally, these antimicrobial agents have almost similar efficacy, with cure rates around 58% to 92% after 1 month of treatment. Nevertheless, these results are temporary, leading to recurrence or re-infection at rates above 50% within 6-12 months of treatment. The reasons for this high relapse rate remain unclear. However, it appears that, with the formation of bacterial biofilms, these recommended therapies only temporarily eradicated BV-associated microorganisms, or these bacteria are reintroduced in the vagina by their sex partners. Further, the presence of some BV-associated bacteria such as Peptoniphilus lacrimalis, Megasphaera type 2 and BVAB-1 to 3 at the beginning of treatment is strongly related to BV recurrence, thus causing antibiotic failure. To this end, two recent studies have examined the acceptability, tolerability, and especially the efficacy of concomitant partner treatment to improve the cure of BV. The first study by Schwebke et al, showed no significant reduction in BV recurrence in female partners after treatment of the male partner with multidose metronidazole, although women whose partners adhered to multidose metronidazole were less likely to fail treatment. The second study showed that simultaneous partner treatment had a significant change in the overall composition of genital microbiota in both partners immediately after treatment.

3.5.2 Non-Antibiotic Therapies

As antibiotic treatments can have a negative impact on the stability of the vaginal flora, Lactobacillus probiotics, an alternative and complementary therapy to antibiotic treatment, has been developed to help restore and maintain the healthy vaginal flora. Probiotics consist of living microorganisms that confer a health benefit on the host when they are administered in an appropriate quantity. Nine studies from 1989 to 2014 tested the effectiveness of vaginal or oral Lactobacillus probiotics. The results showed that both oral and vaginal Lactobacillus treatments were effective in curing acute BV. On balance, the application of Lactobacillus in the form of vaginal capsules (containing≥108 CFU of Lactobacillus strains per dose) or a fermented milk product (containing≥5×109 CFU of Lactobacillus strains per dose) may be an equally effective alternative to standard antibiotic capsules. Only the strains L. reuteri RC-14 and L. rhamnonus GR-1 have positive clinical effects (; Ouarabi et al., 2017). Administrated orally (twice daily) or vaginally (once weekly), probiotics may restore the normal Lactobacillus-dominated microbiota and reduce BV recurrence. Nevertheless, probiotics have had minimal success in African women.

In the same context, a new study on the applicability of three strains of Lactobacillus spp. (Lactobacillus delbrueckii DM8909, Lactiplantibacillus plantarum ATCC14917 and Lactiplantibacillus plantarum ZX27) according to their in vitro probiotic capacities. These three Lactobacillus spp. strains have shown efficacy in the treatment of BV by limiting the growth, adhesion, biofilm formation and virulence properties of G. vaginalis.

In addition, sucrose-containing products may promote recolonization, since sucrose is metabolized by Lactobacilli. A triple-blind randomized clinical trial compared the efficacy of a sucrose vaginal gel versus a metronidazole vaginal gel for 5 days in 70 women with diagnosed BV. The sucrose vaginal gel was as effective as metronidazole treatment, according to this individual RCT.

Another option is to combine Lactobacilli with estriol. Two studies, a PC-RCT and a head-to-head RCT, were conducted on the efficacy of vaginal capsules containing L. acidophilus and 0.03 mg estriol (Gynofor®) in BV. Compared to placebo, the cure rate of BV was significantly higher in the treated group, but according to the comparative study, the combination of estriol and Lactobacilli is equivalent, but not better, results than antibiotic treatment.

In terms of method of application, vaginal suppositories deposit Lactobacillus strains directly on the vaginal mucosa, whereas oral probiotics survive gastrointestinal transit and increase the number of strains in the colon and feces. In turn, this may promote recolonization of the vagina due to the proximity of the rectum and vagina.

3.5.3 New Emerging Therapies

The management of BV urgently requires implementation of new therapeutic strategies. To disrupt BV-associated biofilms, studies are underway to investigate the role of novel agents such as DNases, retrocyclines, antiseptics, and plant-derived compounds in the treatment of BV. Dequalinium chloride, an antiseptic, has reported similar efficacy to clindamycin intravaginal cream. Thymol, a molecule found in thyme essential oil, has shown an inhibitory effect on biofilms in vitro. The application of acidifying agents, such as vitamin C or buffering agents (polycarbophil or boric acid), in combination with a nitroimidazole antibiotic, has been demonstrated to reduce the recurrence of BV, potentially by destructuring the vaginal biofilm.

In this regard, other promising therapeutic agents for the treatment of BV are under investigation. Including DNase agents that can disrupt vaginal biofilms by targeting extracellular DNA essential for their structural integrity, retrocyclin 101, a synthetic cyclic antimicrobial peptide that inhibits the growth and development of G. vaginalis in vitro, and the amphoteric tenside pessary (WO3191), which disrupts biofilms after metronidazole treatment and promotes the growth of Lactobacillus species.

Furthermore, given the success demonstrated by fecal microbiota transplant (FMT) in the management of various intestinal disorders and diseases such as recurrent Clostridium difficile infection, pseudomembranous colitis, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), the use of vaginal microbiota transplantation (VMT) in BV treatment is a new therapeutic approach that modulates the vaginal microbiota in order to eradicate this scourge and reduce adverse gynecological outcomes.

Given the high rates of recurrence and relapse, research is needed to identify and evaluate these novel biofilm-disrupting treatment strategies.

4 Conclusions and Perspectives

The taxonomic composition and bacterial proportion of the vaginal microbiota are under the influence of intrinsic and external factors over the female lifespan. In the last decades, understanding of the bacterial diversity of this ecosystem has been increased by molecular methods. Dominated by Lactobacilli that protect against infection, the vaginal flora of healthy women is less complex than that of patients with BV, which presents a diverse microbiota containing numerous obligate anaerobic and uncultivable species. This polymicrobial condition is associated with relatively uncomplicated clinical symptoms that do not occur in all affected women, thus complicating the determination of its etiology. Treatment is usually unsuccessful, with a high rate of relapse. Future studies that thoroughly examine the vaginal bacterial community are needed to cultivate the bacteria associated with BV and its treatment failure, in order to study antibiotic resistance and to establish more effective alternative therapeutic strategies that reduce BV symptoms as well as its associated complications. Overall, unlocking the enigma of the pathogenesis of BV is key for the prevention and management of this public health problem.

Author Contributions

LAC, FF, and KD have equally contributed to the preparation of this manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was funded by the Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, the National Research Agency under the “Investissements d’avenir” programme, reference ANR-10-IAHU-03, the Region Provence Alpes Côte d’Azur and European FEDER PRIMI funding.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References 160

  1. 1.

    Achilles S. L. Austin M. N. Meyn L. A. Mhlanga F. Chirenje Z. M. Hillier S. L. (2018 ). Impact of Contraceptive Initiation on Vaginal Microbiota. Am. J. Obstet. Gynecol. 218 (6), 622–e15

    Not in our library10.1016/j.ajog.2018.02.017

  2. 2.

    Afolabi B. B. Moses O. E. Oduyebo O. O. (2016 ). “Bacterial Vaginosis and Pregnancy Outcome in Lagos, Nigeria,” in Open Forum Infectious Diseases, vol. 3. (Oxford: Oxford University Press), ofw030

    Not in our library10.1093/ofid/ofw030

  3. 3.

    Africa C. W. J. Nel J. Stemmet M. (2014 ). Anaerobes and Bacterial Vaginosis in Pregnancy: Virulence Factors Contributing to Vaginal Colonisation. Int. J. Environ. Res. Public Health 11 (7), 6979–70005

    Not in our library10.3390/ijerph110706979

  4. 4.

    Aldunate M. Tyssen D. Johnson A. Zakir T. Sonza S. Moench T.. (2013 ). Vaginal Concentrations of Lactic Acid Potently Inactivate HIV. J. Antimicrob. Chemother. 68 (9), 2015–2255

    Not in our library10.1093/jac/dkt156

  5. 5.

    Algburi A. Zhang Y. Weeks R. Comito N. Zehm S. Pinto J.. (2017 ). Gemini Cationic Amphiphiles Control Biofilm Formation by Bacterial Vaginosis Pathogens. Antimicrob. Agents Chemother. 61 (12), e00650–e00175

    Not in our library10.1128/aac.00650-17

  6. 6.

    Alves P. Castro J. Sousa C. Cereija T. B. Cerca N. (2014 ). Gardnerella Vaginalis Outcompetes 29 Other Bacterial Species Isolated From Patients With Bacterial Vaginosis, Using in an in Vitro Biofilm Formation Model. J. Infect. Dis. 210 (4), 593–965

    Not in our library10.1093/infdis/jiu131

  7. 7.

    Amsel R. Totten P. A. Spiegel C. A. Chen K. C. S. Eschenbach D. Holmes K. K. (1983 ). Nonspecific Vaginitis: Diagnostic Criteria and Microbial and Epidemiologic Associations. Am. J. Med. 74 (1), 14–225

    Not in our library10.1016/0002-9343(83)91112-9

  8. 8.

    Antonucci F. Mirandola W. Fontana C. Fontana C. (2017 ). Comparison Between Nugent’s and Hay/Ison Scoring Criteria for the Diagnosis of Bacterial Vaginosis in WASP Prepared Vaginal Samples. Clin. Investig. (Lond.) 7, 89–93

    Not in our library10.4172/clinical-investigation.1000116

  9. 9.

    Aslan E. Bechelaghem N. (2018 ). To ‘Douche’or Not to ‘Douche’: Hygiene Habits May Have Detrimental Effects on Vaginal Microbiota. J. Obstet. Gynaecol. 38 (5), 678–815

    Not in our library10.1080/01443615.2017.1395398

  10. 10.

    Babu G. Ganvelu Singaravelu B. Srikumar R. Reddy S. V. (2017 ). Comparative Study on the Vaginal Flora and Incidence of Asymptomatic Vaginosis Among Healthy Women and in Women With Infertility Problems of Reproductive Age. J. Clin. Diagn. Res. 11 (8), DC18

    Not in our library10.7860/jcdr/2017/28296.10417

  11. 11.

    Bacterial Vaginosis (2015 ) STD Treatment Guidelines. Available at: https://www.cdc.gov/std/tg2015/bv.html (Accessed April 14, 2018).

    Not in our library

  12. 12.

    Bagnall P. Rizzolo D. (2017 ). Bacterial Vaginosis: A Practical Review. J. Am. Acad. Physician Assist. 30 (12), 15–215

    Not in our library10.1097/01.jaa.0000526770.60197.fa

  13. 13.

    Beebout C. J. Eberly A. R. Werby S. H. Reasoner S. A. Brannon J. R. De S.. (2019 ). Respiratory Heterogeneity Shapes Biofilm Formation and Host Colonization in Uropathogenic Escherichia Coli. MBio 10 (2), e02400–e02185

    Not in our library10.1128/mbio.02400-18

  14. 14.

    Bilardi J. Walker S. McNair R. Mooney-Somers J. Temple-Smith M. Bellhouse C.. (2016 a). Women’s Management of Recurrent Bacterial Vaginosis and Experiences of Clinical Care: A Qualitative Study. PLoS One 11 (3), e01517945

    Not in our library10.1371/journal.pone.0151794

  15. 15.

    Bilardi J. Walker S. Mooney-Somers J. Temple-Smith M. McNair R. Bellhouse C.. (2016 b). Women’s Views and Experiences of the Triggers for Onset of Bacterial Vaginosis and Exacerbating Factors Associated With Recurrence. PLoS One 11 (3), e01502725

    Not in our library10.1371/journal.pone.0150272

  16. 16.

    Bitew A. Abebaw Y. Bekele D. Mihret A. (2017 ). Prevalence of Bacterial Vaginosis and Associated Risk Factors Among Women Complaining of Genital Tract Infection. Int. J. Microbiol. 2017, 4919404

    Not in our library10.1155/2017/4919404

  17. 17.

    Borges S. Silva J. Teixeira P. (2014 ). The Role of Lactobacilli and Probiotics in Maintaining Vaginal Health. Arch. Gynecol. Obstet. 289 (3), 479–895

    Not in our library10.1007/s00404-013-3064-9

  18. 18.

    Bradshaw C. S. Brotman R. M. (2015 ). Making Inroads Into Improving Treatment of Bacterial Vaginosis–Striving for Long-Term Cure. BMC Infect. Dis. 15 (1), 1–125

    Not in our library10.1186/s12879-015-1027-4

  19. 19.

    Bradshaw C. S. Pirotta M. De Guingand D. Hocking J. S. Morton A. N. Garland S. M.. (2012 ). Efficacy of Oral Metronidazole With Vaginal Clindamycin or Vaginal Probiotic for Bacterial Vaginosis: Randomised Placebo-Controlled Double-Blind Trial. PLoS One 7 (4), e345405

    Not in our library10.1371/journal.pone.0034540

  20. 20.

    Bradshaw C. S. Sobel J. D. (2016 ). Current Treatment of Bacterial Vaginosis—Limitations and Need for Innovation. J. Infect. Dis. 214 (suppl_1), S14–S20

    Not in our library10.1093/infdis/jiw159

  21. 21.

    Bradshaw C. S. Tabrizi S. N. Fairley C. K. Morton A. N. Rudland E. Garland S. M. (2006 ). The Association of Atopobium Vaginae and Gardnerella Vaginalis With Bacterial Vaginosis and Recurrence After Oral Metronidazole Therapy. J. Infect. Dis. 194 (6), 828–365

    Not in our library10.1086/506621

  22. 22.

    Braga P. C. Dal Sasso M. Culici M. Spallino A. (2010 ). Inhibitory Activity of Thymol on Native and Mature Gardnerella Vaginalis Biofilms: In Vitro Study. Arzneimittelforschung 60 (11), 675–815

    Not in our library10.1055/s-0031-1296346

  23. 23.

    Breding K. Selbing A. Farnebäck M. (2020 ). Diagnosis of Bacterial Vaginosis Using a Novel Molecular Real-Time PCR Test. J. Womens Health Gynecol. 7, 1–7.

    Not in our library

  24. 24.

    Bretelle F. Rozenberg P. Pascal A. Favre R. Bohec C. Loundou A.. (2015 ). High Atopobium Vaginae and Gardnerella Vaginalis Vaginal Loads Are Associated With Preterm Birth. Clin. Infect. Dis. 60 (6), 860–675

    Not in our library10.1093/cid/ciu966

  25. 25.

    Briselden A. M. Moncla B. J. Stevens C. E. Hillier S. L. (1992 ). Sialidases (Neuraminidases) in Bacterial Vaginosis and Bacterial Vaginosis-Associated Microflora. J. Clin. Microbiol. 30 (3), 663–665

    Not in our library10.1128/jcm.30.3.663-666.1992

  26. 26.

    Brotman R. M. (2011 ). Vaginal Microbiome and Sexually Transmitted Infections: An Epidemiologic Perspective. J. Clin. Invest. 121 (12), 4610–4617

    Not in our library10.1172/jci57172

  27. 27.

    Brotman R. M. Shardell M. D. Gajer P. Kathleen Tracy J. Zenilman J. M. Ravel J.. (2014 ). Interplay Between the Temporal Dynamics of the Vaginal Microbiota and Human Papillomavirus Detection. J. Infect. Dis. 210 (11), 1723–1335

    Not in our library10.1093/infdis/jiu330

  28. 28.
    Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin · 2018
    No notice
  29. 29.

    Camus C. Penaranda G. Khiri H. Camiade S. Molet L. Lebsir M.. (2021 ). Acceptability and Efficacy of Vaginal Self-Sampling for Genital Infection and Bacterial Vaginosis: A Cross-Sectional Study. PLoS One 16 (11), e02600215

    Not in our library10.1371/journal.pone.0260021

  30. 30.

    Cartwright C. P. Lembke B. D. Ramachandran K. Body B. A. Nye M. B. Rivers C. A.. (2012 ). Development and Validation of a Semiquantitative, Multitarget PCR Assay for Diagnosis of Bacterial Vaginosis. J. Clin. Microbiol. 50 (7), 2321–2295

    Not in our library10.1128/jcm.00506-12

  31. 31.

    Cartwright C. P. Pherson A. J. Harris A. B. Clancey M. S. Nye M. B. (2018 ). Multicenter Study Establishing the Clinical Validity of a Nucleic-Acid Amplification–Based Assay for the Diagnosis of Bacterial Vaginosis. Diagn. Microbiol. Infect. Dis. 92 (3), 173–785

    Not in our library10.1016/j.diagmicrobio.2018.05.022

  32. 32.

    Castro J. França A. Bradwell K. R. Serrano M. G. Jefferson K. K. Cerca N. (2017 ). Comparative Transcriptomic Analysis of Gardnerella Vaginalis Biofilms vs. Planktonic Cultures Using RNA-Seq. NPJ Biofilms Microbiomes 3 (1), 1–75

    Not in our library10.1038/s41522-017-0012-7

  33. 33.
    Unveiling the role of Gardnerella vaginalis in polymicrobial Bacterial Vaginosis biofilms: the impact of other vaginal pathogens living as neighbors · 2019
    No notice
  34. 34.

    Cherpes T. L. Hillier S. L. Meyn L. A. Busch J. L. Krohn M. A. (2008 ). A Delicate Balance: Risk Factors for Acquisition of Bacterial Vaginosis Include Sexual Activity, Absence of Hydrogen Peroxide-Producing Lactobacilli, Black Race, and Positive Herpes Simplex Virus Type 2 Serology. Sex. Transm. Dis. 35 (1), 78–835

    Not in our library10.1097/olq.0b013e318156a5d0

  35. 35.

    Coleman J. S. Gaydos C. A. (2018 ). Molecular Diagnosis of Bacterial Vaginosis: An Update. J. Clin. Microbiol. 56 (9), e00342-18

    Not in our library10.1128/jcm.00342-18

  36. 36.

    Cristiano L. Rampello S. Noris C. Valota V. (1996 ). Bacterial Vaginosis: Prevalence in an Italian Population of Asymptomatic Pregnant Women and Diagnostic Aspects. Eur. J. Epidemiol. 12 (4), 383–905

    Not in our library10.1007/bf00145302

  37. 37.

    Daliri E. B. M. Lee B. H. (2015 ). New Perspectives on Probiotics in Health and Disease. Food Sci. Hum. Wellness 4 (2), 56–65

    Not in our library10.1016/j.fshw.2015.06.002

  38. 38.

    Danielsson D. Teigen P. K. Moi H. (2011 ). The Genital Econiche: Focus on Microbiota and Bacterial Vaginosis. Ann. N. Y. Acad. Sci. 1230(1), 48–58

    Not in our library10.1111/j.1749-6632.2011.06041.x

  39. 39.

    Deidda F. Amoruso A. Allesina S. Pane M. Graziano T. Del Piano M.. (2016 ). In Vitro Activity of Lactobacillus Fermentum LF5 Against Different Candida Species and Gardnerella Vaginalis: A New Perspective to Approach Mixed Vaginal Infections? J. Clin. Gastroenterol. 50, S168–S170

    Not in our library10.1097/mcg.0000000000000692

  40. 40.

    DeLong K. Bensouda S. Zulfiqar F. Zierden H. C. Hoang T. M. Abraham A. G.. (2019 ). Conceptual Design of a Universal Donor Screening Approach for Vaginal Microbiota Transplant. Front. Cell. Infect. Microbiol. 9, 306

    Not in our library10.3389/fcimb.2019.00306

  41. 41.

    Dessai F. Nyikjrenda M. Sebitloane M. Abbai N. (2020 ). Diagnostic Evaluation of the BD Affirm VPIII Assay as a Point-Of-Care Test for the Diagnosis of Bacterial Vaginosis, Trichomoniasis and Candidiasis. Int. J. STD AIDS 31 (4), 303–115

    Not in our library10.1177/0956462419895684

  42. 42.

    Dickey L. J. Nailor M. D. Sobel J. D. (2009 ). Guidelines for the Treatment of Bacterial Vaginosis: Focus on Tinidazole. Ther. Clin. Risk Manage. 5, 485

    Not in our library10.2147/tcrm.s3777

  43. 43.

    Donders G. Bellen G. Donders F. Pinget J. Vandevelde I. Michiels T.. (2017 ). Improvement of Abnormal Vaginal Flora in Ugandan Women by Self-Testing and Short Use of Intravaginal Antimicrobials. Eur. J. Clin. Microbiol. Infect. Dis. 36, (4)

    Not in our library10.1007/s10096-016-2856-9

  44. 44.

    Donders G. G. G. Van Bulck B. Van de Walle P. Kaiser R. R. Pohlig G. Gonser S.. (2010 ). Effect of Lyophilized Lactobacilli and 0.03 Mg Estriol (Gynoflor®) on Vaginitis and Vaginosis With Disrupted Vaginal Microflora: A Multicenter, Randomized, Single-Blind, Active-Controlled Pilot Study. Gynecol. Obstet. Invest. 70 (4), 264–725

    Not in our library10.1159/000314016

  45. 45.

    Donders G. G. G. Zodzika J. Rezeberga D. (2014 ). Treatment of Bacterial Vaginosis: What We Have and What We Miss. Expert Opin. Pharmacother. 15 (5), 645–575

    Not in our library10.1517/14656566.2014.881800

  46. 46.

    Fenollar F. Raoult D. (2016 ). Does Bacterial Vaginosis Result From Fecal Transplantation? J. Infect. Dis. 214 (11), 17845

    Not in our library10.1093/infdis/jiw472

  47. 47.

    Fettweis J. M. Brooks J. P. Serrano M. G. Sheth N. U. Girerd P. H. Edwards D. J.. (2014 ). Differences in Vaginal Microbiome in African American Women Versus Women of European Ancestry. Microbiology 160 Pt 10), 2272

    Not in our library10.1099/mic.0.081034-0

  48. 48.

    Forcey D. S. Vodstrcil L. A. Hocking J. S. Fairley C. K. Law M. McNair R. P.. (2015 ). Factors Associated With Bacterial Vaginosis Among Women Who Have Sex With Women: A Systematic Review. PLoS One 10 12), e01419055

    Not in our library10.1371/journal.pone.0141905

  49. 49.

    Fredricks D. N. Fiedler T. L. Marrazzo J. M. (2005 ). Molecular Identification of Bacteria Associated With Bacterial Vaginosis. N. Engl. J. Med. 353 (18), 1899–19115

    Not in our library10.1056/nejmoa043802

  50. 50.

    Fredricsson B. Englund K. Weintraub L. Ölund A. Nord C.-E. (1989 ). Bacterial Vaginosis Is Not a Simple Ecological Disorder. Gynecol. Obstet. Invest. 28 (3), 156–605

    Not in our library10.1159/000293556

  51. 51.

    Gajer P. Brotman R. M. Bai G. Sakamoto J. Schütte U. M. Zhong X.. (2012 ). Temporal Dynamics of the Human Vaginal Microbiota. Sci. Transl. Med. 4, 132ra52

    Not in our library10.1126/scitranslmed.3003605

  52. 52.

    Gallo M. F. Warner L. King C. C. Sobel J. D. Klein R. S. Cu-Uvin S.. (2011 ). Association Between Semen Exposure and Incident Bacterial Vaginosis. Infect. Dis. Obstet. Gynecol. 2011, 842652

    Not in our library10.1155/2011/842652

  53. 53.

    Gardner H. L. Dukes C. D. (1955 ). Haemophilus Vaginalis Vaginitis: A Newly Defined Specific Infection Previously Classified ‘Nonspecific’ Vaginitis. Am. J. Obstet. Gynecol. 69 (5), 962–765

    Not in our library10.1016/0002-9378(55)90095-8

  54. 54.

    Gaydos C. A. Beqaj S. Schwebke J. R. Lebed J. Smith B. Davis T. E.. (2017 ). Clinical Validation of a Test for the Diagnosis of Vaginitis. Obstet. Gynecol. 130 (1), 1815

    Not in our library10.1097/aog.0000000000002090

  55. 55.

    Georgijević A. Cjukić-Ivancević S. Bujko M. (2000 ). Bacterial Vaginosis. Epidemiology and Risk Factors. Srp. Arh. Celok. Lek. 128 (1–2), 29–33.

    Not in our library

  56. 56.

    Gilbert N. M. Lewis W. G. Li G. Sojka D. K. Bernard Lubin J. Lewis A. L. (2019 ). Gardnerella Vaginalis and Prevotella Bivia Trigger Distinct and Overlapping Phenotypes in a Mouse Model of Bacterial Vaginosis. J. Infect. Dis. 220 (7), 1099–11085

    Not in our library10.1093/infdis/jiy704

  57. 57.

    Gonzalez Pedraza Aviles P. Ortiz Zaragoza M. C. Irigoyen Coria A. (1999 ). Bacterial Vaginosis a Broad Overview. Rev. Latinoam. Microbiol. Mexico 41 (1), 25–345.

    Not in our library

  58. 58.

    Gottschick C. Deng Z.-L. Vital M. Masur C. Abels C. Pieper D. H.. (2017 ). Treatment of Biofilms in Bacterial Vaginosis by an Amphoteric Tenside Pessary-Clinical Study and Microbiota Analysis. Microbiome 5 (1), 1–155

    Not in our library10.1186/s40168-017-0326-y

  59. 59.

    Green K. A. Zarek S. M. Catherino W. H. (2015 ). Gynecologic Health and Disease in Relation to the Microbiome of the Female Reproductive Tract. Fertil. Steril. 104 (6), 1351–1575

    Not in our library10.1016/j.fertnstert.2015.10.010

  60. 60.

    Guédou F. A. Van Damme L. Deese J. Crucitti T. Becker M. Mirembe F.. (2013 ). Behavioural and Medical Predictors of Bacterial Vaginosis Recurrence Among Female Sex Workers: Longitudinal Analysis From a Randomized Controlled Trial. BMC Infect. Dis. 131, 1–115

    Not in our library10.1186/1471-2334-13-208

  61. 61.

    Hallén A. Jarstrand C. Påhlson C. (1992 ). Treatment of Bacterial Vaginosis With Lactobacilli. Sex. Transm. Dis. 19 (3), 146–148

    Not in our library10.1097/00007435-199205000-00007

  62. 62.

    Hardy L. Jespers V. Abdellati S. De Baetselier I. Mwambarangwe L. Musengamana V.. (2016 ). A Fruitful Alliance: The Synergy Between Atopobium Vaginae and Gardnerella Vaginalis in Bacterial Vaginosis-Associated Biofilm. Sex. Transm. Infect. 92 (7), 487–915

    Not in our library10.1136/sextrans-2015-052475

  63. 63.

    Hay P. E. (2002 ). Bacterial Vaginosis as a Mixed Infection. In: Brogden K. Guthmiller J., editors. Polymicrobial Diseases. Washington (DC)

    Not in our library10.1128/9781555817947.ch7

  64. 64.

    Hemalatha R. Mastromarino P. Ramalaxmi B. A. Balakrishna N. V. Sesikeran B. (2012 ). Effectiveness of Vaginal Tablets Containing Lactobacilli Versus PH Tablets on Vaginal Health and Inflammatory Cytokines: A Randomized, Double-Blind Study. Eur. J. Clin. Microbiol. Infect. Dis. 31 (11), 3097–3105

    Not in our library10.1007/s10096-012-1671-1

  65. 65.

    Hickey R. J. Forney L. J. (2014 ). Gardnerella Vaginalis Does Not Always Cause Bacterial Vaginosis. J. Infect. Dis. 210 (10), 1682–1835

    Not in our library10.1093/infdis/jiu303

  66. 66.

    Hickey R. J. Zhou X. Pierson J. D. Ravel J. Forney L. J. (2012 ). Understanding Vaginal Microbiome Complexity From an Ecological Perspective. Trans. Res. 160 (4), 267–825

    Not in our library10.1016/j.trsl.2012.02.008

  67. 67.

    Hilbert D. W. Smith W. L. Chadwick S. G. Toner G. Mordechai E. Adelson M. E.. (2016 ). Development and Validation of a Highly Accurate Quantitative Real-Time PCR Assay for Diagnosis of Bacterial Vaginosis. J. Clin. Microbiol. 54 (4), 1017–1245

    Not in our library10.1128/jcm.03104-15

  68. 68.

    Hogan V. K. Culhane J. F. Hitti J. Rauh V. A. McCollum K. F. Agnew K. J. (2007 ). Relative Performance of Three Methods for Diagnosing Bacterial Vaginosis During Pregnancy. Matern. Child Health J. 11 (6), 532–395

    Not in our library10.1007/s10995-007-0205-4

  69. 69.

    Hooven T. A. Randis T. M. Hymes S. R. Rampersaud R. Ratner A. J. (2012 ). Retrocyclin Inhibits Gardnerella Vaginalis Biofilm Formation and Toxin Activity. J. Antimicrob. Chemother. 67 (12), 2870–2725

    Not in our library10.1093/jac/dks305

  70. 70.

    Hou D. Zhou X. Zhong X. Settles M. L. Herring J. Wang L.. (2013 ). Microbiota of the Seminal Fluid From Healthy and Infertile Men. Fertil. Steril. 100 (5), 1261–1695

    Not in our library10.1016/j.fertnstert.2013.07.1991

  71. 71.

    Huang B. Fettweis J. M. Brooks J. P. Jefferson K. K. Buck G. A. (2014 ). The Changing Landscape of the Vaginal Microbiome. Clin. Lab. Med. 34 (4), 747–615

    Not in our library10.1016/j.cll.2014.08.006

  72. 72.

    Hummelen R. Hemsworth J. Reid G. (2010 ). Clinical Study Comparing Probiotic Lactobacillus GR-1 and RC-14 With Metronidazole Vaginal Gel to Treat Symptomatic Bacterial Vaginosis. Nutrients 2 (6), 626

    Not in our library10.3390/nu2060626

  73. 73.

    Hymes S. R. Randis T. M. Sun T. Y. Ratner A. J. (2013 ). DNase Inhibits Gardnerella Vaginalis Biofilms In Vitro and In Vivo. J. Infect. Dis. 207 (10), 1491–1975

    Not in our library10.1093/infdis/jit047

  74. 74.

    Ison C. A. Hay P. E. (2002 ). Validation of a Simplified Grading of Gram Stained Vaginal Smears for Use in Genitourinary Medicine Clinics. Sex. Transm. Infect. 78 (6), 413–415

    Not in our library10.1136/sti.78.6.413

  75. 75.

    Kairys N. Garg M. (2017 ). Bacterial Vaginosis. In: StatPearls. (Treasure Island (FL): StatPearls Publishing); 2021.

    Not in our library

  76. 76.

    Kenyon C. Colebunders R. Crucitti T. (2013 ). The Global Epidemiology of Bacterial Vaginosis: A Systematic Review. Am. J. Obstet. Gynecol. 209 (6), 505–235

    Not in our library10.1016/j.ajog.2013.05.006

  77. 77.

    Kenyon C. R. Osbak K. (2014 ). Recent Progress in Understanding the Epidemiology of Bacterial Vaginosis. Curr. Opin. Obstet. Gynecol. 26 (6), 448–545

    Not in our library10.1097/gco.0000000000000112

  78. 78.

    Kero K. Rautava J. Syrjänen K. Grenman S. Syrjänen S. (2017 ). Association of Asymptomatic Bacterial Vaginosis With Persistence of Female Genital Human Papillomavirus Infection. Eur. J. Clin. Microbiol. Infect. Dis. 36 (11), 2215–2219

    Not in our library10.1007/s10096-017-3048-y

  79. 79.

    Khan K. Shah R. Gautam M. Patil S. (2007 ). Clue Cells. Indian J. Sex. Transm. Dis. 28 (2), 1085

    Not in our library10.4103/0253-7184.39018

  80. 80.

    Khatoon R. Ahmad S. Jahan N. (2013 ). OSOM BV Blue Test: A New Point-Of-Care Test for Diagnosing Bacterial Vaginosis and Its Comparison With Gram Staining. Afr. J. Microbiol. Res. 7 (32), 4103–4106

    Not in our library10.5897/ajmr2013.5957

  81. 81.
    Comparing the effect of sucrose gel and metronidazole gel in treatment of clinical symptoms of bacterial vaginosis: a randomized controlled trial · 2018
    Not checked
  82. 82.

    Koumans E. H. Sternberg M. Bruce C. McQuillan G. Kendrick J. Sutton M.. (2007 ). The Prevalence of Bacterial Vaginosis in the United States 2001–2004; Associations With Symptoms, Sexual Behaviors, and Reproductive Health. Sex. Transm. Dis. 34 (11), 864–695

    Not in our library10.1097/olq.0b013e318074e565

  83. 83.

    Kumar N. Behera B. Sagiri S. S. Pal K. Ray S. S. Roy S. (2011 ). Bacterial Vaginosis: Etiology and Modalities of Treatment—a Brief Note. J. Pharm. Bioallied Sci. 3 (4), 496

    Not in our library10.4103/0975-7406.90102

  84. 84.

    Laghi L. Picone G. Cruciani F. Brigidi P. Calanni F. Donders G.. (2014 ). Rifaximin Modulates the Vaginal Microbiome and Metabolome in Women Affected by Bacterial Vaginosis. Antimicrob. Agents Chemother. 58 (6), 3411–3205

    Not in our library10.1128/aac.02469-14

  85. 85.

    Lepargneur J.-P. Rousseau V. (2002 ). Rôle Protecteur De La Flore De Doderleïn. J. Gynécol. Obstét. Biol. Reprod. 31 (5), 485–494.

    Not in our library

  86. 86.

    Lewis F. M. T. Bernstein K. T. Aral S. O. (2017 ). Vaginal Microbiome and Its Relationship to Behavior, Sexual Health, and Sexually Transmitted Diseases. Obstet. Gynecol. 129 (4), 6435

    Not in our library10.1097/aog.0000000000001932

  87. 87.

    Li J. McCormick J. Bocking A. Reid G. (2012 ). Importance of Vaginal Microbes in Reproductive Health. Reprod. Sci. 19 (3), 235–425

    Not in our library10.1177/1933719111418379

  88. 88.

    Ling Z. Liu X. Chen W. Luo Y. Yuan L. Xia Y.. (2013 ). The Restoration of the Vaginal Microbiota After Treatment for Bacterial Vaginosis With Metronidazole or Probiotics. Microb. Ecol. 65 (3), 773–805

    Not in our library10.1007/s00248-012-0154-3

  89. 89.

    Liu G.-j. Wang B. Zhang Y. Xing G.-w. Yang X. Wang S. (2018 ). A Tetravalent Sialic Acid-Coated Tetraphenylethene Luminogen With Aggregation-Induced Emission Characteristics: Design, Synthesis and Application for Sialidase Activity Assay, High-Throughput Screening of Sialidase Inhibitors and Diagnosis of Bacterial Va. Chem. Commun. 54 (76), 10691–10945

    Not in our library10.1039/c8cc06300a

  90. 90.
    Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions · 2016
    No notice
  91. 91.

    Machado A. Cerca N. (2015 ). Influence of Biofilm Formation by Gardnerella Vaginalis and Other Anaerobes on Bacterial Vaginosis. J. Infect. Dis. 212 (12), 1856–1615

    Not in our library10.1093/infdis/jiv338

  92. 92.

    Madhivanan P. Krupp K. Li T. Ravi K. Selezneva J. Srinivas V.. (2014 ). Performance of BVBlue Rapid Test in Detecting Bacterial Vaginosis Among Women in Mysore, India. Infect. Dis. Obstet. Gynecol. 2014, 908313

    Not in our library10.1155/2014/908313

  93. 93.

    Majigo M. V. Kashindye P. Mtulo Z. (2021 ). Bacterial Vaginosis, the Leading Cause of Genital Discharge Among Women Presenting With Vaginal Infection in Dar Es Salaam, Tanzania. Afr. Health Sci. 21 (2), 531–375

    Not in our library10.4314/ahs.v21i2.7

  94. 94.

    Makarova K. Slesarev A. Wolf Y. Sorokin A. Mirkin B. Koonin E.. (2006 ). Comparative Genomics of the Lactic Acid Bacteria. Proc. Natl. Acad. Sci. 103 (42), 15611–15165

    Not in our library10.1073/pnas.0607117103

  95. 95.

    Mårdh P. A. (1993 ). The Definition and Epidemiology of Bacterial Vaginosis. Rev. Fr. Gynecol. Obstet. 88 (3 Pt 2), 195–197.

    Not in our library

  96. 96.

    Margolis E. Fredricks D. N. (2015 ). “Bacterial Vaginosis-Associated Bacteria,” in Molecular Medical Microbiology (Bonston: Elsevier), 1487–1496.

    Not in our library

  97. 97.

    Marrazzo J. M. Fiedler T. L. Srinivasan S. Thomas K. K. Liu C. Ko D.. (2012 ). Extravaginal Reservoirs of Vaginal Bacteria as Risk Factors for Incident Bacterial Vaginosis. J. Infect. Dis. 205 (10), 1580–1885

    Not in our library10.1093/infdis/jis242

  98. 98.

    Marrazzo J. M. Hillier S. L. (2013 ). Bacterial Vaginosis. Sex. Transm. Dis., 463–498

    Not in our library10.1016/b978-0-12-391059-2.00018-8

  99. 99.

    Marrazzo J. M. Thomas K. K. Fiedler T. L. Ringwood K. Fredricks D. N. (2008 ). Relationship of Specific Vaginal Bacteria and Bacterial Vaginosis Treatment Failure in Women Who Have Sex With Women. Ann. Intern. Med. 149 (1), 20–285

    Not in our library10.7326/0003-4819-149-1-200807010-00006

  100. 100.

    Mastromarino P. Macchia S. Meggiorini L. Trinchieri V. Mosca L. Perluigi M.. (2009 ). Effectiveness of Lactobacillus-Containing Vaginal Tablets in the Treatment of Symptomatic Bacterial Vaginosis. Clin. Microbiol. Infect. 15 (1), 67–74

    Not in our library10.1111/j.1469-0691.2008.02112.x

  101. 101.

    McClelland R. S. Lingappa J. R. Srinivasan S. Kinuthia J. John-Stewart G. C. Jaoko W.. (2018 ). Evaluation of the Association Between the Concentrations of Key Vaginal Bacteria and the Increased Risk of HIV Acquisition in African Women From Five Cohorts: A Nested Case-Control Study. Lancet Infect. Dis. 18 (5), 554–645

    Not in our library10.1016/s1473-3099(18)30058-6

  102. 102.

    Menard J. P. Fenollar F. Henry M. Bretelle F. Raoult D. (2008 ). Molecular Quantification of Gardnerella Vaginalis and Atopobium Vaginae Loads to Predict Bacterial Vaginosis. Clin. Infect. Dis. 47 (1), 33–435

    Not in our library10.1086/588661

  103. 103.

    Menard J.-P. Fenollar F. Raoult D. Boubli L. Bretelle F. (2012 ). Self-Collected Vaginal Swabs for the Quantitative Real-Time Polymerase Chain Reaction Assay of Atopobium Vaginae and Gardnerella Vaginalis and the Diagnosis of Bacterial Vaginosis. Eur. J. Clin. Microbiol. Infect. Dis. 31 (4), 513–185

    Not in our library10.1007/s10096-011-1341-8

  104. 104.

    Mendling W. (2016 ). Vaginal Microbiota. In: Schwiertz A. (eds). Microbiota of the Human Body. Advances in Experimental Medicine and Biology. Cham: Springer, vol. 902, p. 83–93

    Not in our library10.1007/978-3-319-31248-4_6

  105. 105.

    Money D. (2005 ). The Laboratory Diagnosis of Bacterial Vaginosis. Can. J. Infect. Dis. Med. Microbiol. 16 (2), 77–79

    Not in our library10.1155/2005/230319

  106. 106.

    Morris M. C. Rogers P. A. Kinghorn G. R. (2001 ). Is Bacterial Vaginosis a Sexually Transmitted Infection? Sex. Transm. Infect. 77 (1), 63–68

    Not in our library10.1136/sti.77.1.63

  107. 107.

    Muhleisen A. \. L. Herbst-Kralovetz M. M. (2016 ). Menopause and the Vaginal Microbiome. Maturitas 91, 42–50

    Not in our library10.1016/j.maturitas.2016.05.015

  108. 108.

    Muzny C. A. Blanchard E. Taylor C. M. Aaron K. J. Talluri R. Griswold M. E.. (2018 ). Identification of Key Bacteria Involved in the Induction of Incident Bacterial Vaginosis: A Prospective Study. J. Infect. Dis. 218 (6), 966–785

    Not in our library10.1093/infdis/jiy243

  109. 109.

    Muzny C. A. Sunesara I. R. Austin E. L. Mena L. A. Schwebke J. R. (2013 ). Bacterial Vaginosis Among African American Women Who Have Sex With Women. Sex. Transm. Dis. 40 (9), 751–555

    Not in our library10.1097/olq.0000000000000004

  110. 110.

    Muzny C. A. Taylor C. M. Swords W. E. Tamhane A. Chattopadhyay D. Cerca N.. (2019 ). An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis. J. Infect. Dis. 220 (9), 1399–14055

    Not in our library10.1093/infdis/jiz342

  111. 111.

    Myziuk L. Romanowski B. Johnson S. C. (2003 ). BVBlue Test for Diagnosis of Bacterial Vaginosis. J. Clin. Microbiol. 41 (5), 1925–1285

    Not in our library10.1128/jcm.41.5.1925-1928.2003

  112. 112.

    Nardis C. Mosca L. Mastromarino P. (2013 ). Vaginal Microbiota and Viral Sexually Transmitted Diseases. Ann. Ig. 25 (5), 443–456

    Not in our library10.7416/ai.2013.1946

  113. 113.

    Nasioudis D. Linhares I. M. Ledger W. J. Witkin S. S. (2017 ). Bacterial Vaginosis: A Critical Analysis of Current Knowledge. BJOG 124 (1), 61–695

    Not in our library10.1111/1471-0528.14209

  114. 114.

    Nelson T. M. Borgogna J. C. Michalek R. D. Roberts D. W. Rath J. M. Glover E. D.. (2018 ). Cigarette Smoking Is Associated With an Altered Vaginal Tract Metabolomic Profile. Sci. Rep. 8 (1), 1–135

    Not in our library10.1038/s41598-017-14943-3

  115. 115.

    Nelson D. B. Hanlon A. L. Wu G. Liu C. Fredricks D. N. (2015 a). First Trimester Levels of BV-Associated Bacteria and Risk of Miscarriage Among Women Early in Pregnancy. Matern. Child Health J. 19 (12), 2682–2875

    Not in our library10.1007/s10995-015-1790-2

  116. 116.

    Nugent R. P. Krohn M. A. Hillier S. L. (1991 ). Reliability of Diagnosing Bacterial Vaginosis Is Improved by a Standardized Method of Gram Stain Interpretation. J. Clin. Microbiol. 29 (2), 297–3015

    Not in our library10.1128/jcm.29.2.297-301.1991

  117. 117.
    Microbial Changes during Pregnancy, Birth, and Infancy · 2016
    No notice
  118. 118.
    Vaginal pH and Microbicidal Lactic Acid When Lactobacilli Dominate the Microbiota · 2013
    No notice
  119. 119.

    Onderdonk A. B. Delaney M. L. Fichorova R. N. (2016 ). The Human Microbiome During Bacterial Vaginosis. Clin. Microbiol. Rev. 29 (2), 223–385

    Not in our library10.1128/cmr.00075-15

  120. 120.

    Parent D. Bossens M. Bayot D. Kirkpatrick C. Graf F. Wilkinson F. E.. (1996 ). Therapy of Bacterial Vaginosis Using Exogenously-Applied Lactobacilli Acidophili and a Low Dose of Estriol: A Placebo-Controlled Multicentric Clinical Trial. Arzneimittelforschung 46 (1), 68–735.

    Not in our library

  121. 121.
    A Prospective, Open-Label Pilot Study of Concurrent Male Partner Treatment for Bacterial Vaginosis · 2021
    Not checked
  122. 122.

    Qian Z. Zhu H. Zhao D. Yang P. Gao F. Lu C.. (2021 ). Probiotic Lactobacillus Sp. Strains Inhibit Growth, Adhesion, Biofilm Formation, and Gene Expression of Bacterial Vaginosis-Inducing Gardnerella Vaginalis. Microorganisms 9 (4), 728

    Not in our library10.3390/microorganisms9040728

  123. 123.

    Ravel J. Gajer P. Abdo Z. Schneider G. M. Koenig S. S. (2011 ). Vaginal Microbiome of Reproductive-Age Women. Proc. Natl. Acad. Sci. U. S. A. 108, 4680–4687

    Not in our library10.1073/pnas.1002611107

  124. 124.

    Redelinghuys M. J. Ehlers M. M. Bezuidenhoudt J. E. Becker P. J. Kock M. M. (2017 ). Assessment of Atopobium Vaginae and Gardnerella Vaginalis Concentrations in a Cohort of Pregnant South African Women. Sex. Transm. Infect. 93 (6), 410–55

    Not in our library10.1136/sextrans-2016-052883

  125. 125.

    Reid (2018 ). Is Bacterial Vaginosis a Disease? Appl. Microbiol. Biotechnol. 102 (2), 553–558

    Not in our library10.1007/s00253-017-8659-9

  126. 126.

    Rodríguez-Nava C. Cortés-Sarabia K. Avila-Huerta M. D. Ortiz-Riaño E. J. Estrada-Moreno A. K. del C Alarcón-Romero L.. (2021 ). Nanophotonic Sialidase Immunoassay for Bacterial Vaginosis Diagnosis. ACS Pharmacol. Trans. Sci. 4 (1), 365–715

    Not in our library10.1021/acsptsci.0c00211

  127. 127.
    The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women · 2014
    Corrected
  128. 128.

    Rousseau V. Lepargneur J. P. Roques C. Remaud-Simeon M. Paul F. (2005 ). Prebiotic Effects of Oligosaccharides on Selected Vaginal Lactobacilli and Pathogenic Microorganisms. Anaerobe 11 (3), 145–153

    Not in our library10.1016/j.anaerobe.2004.12.002

  129. 129.

    Rumyantseva T. Khayrullina G. Guschin A. Donders G. (2019 ). Prevalence of Ureaplasma Spp. And Mycoplasma Hominis in Healthy Women and Patients With Flora Alterations. Diagn. Microbiol. Infect. Dis. 93 (3), 227–315

    Not in our library10.1016/j.diagmicrobio.2018.10.001

  130. 130.

    Schellenberg J. J. Jayaprakash T. P. Gamage N. W. Patterson M. H. Vaneechoutte M. Hill J. E. (2016 ). Gardnerella Vaginalis Subgroups Defined by Cpn 60 Sequencing and Sialidase Activity in Isolates From Canada, Belgium and Kenya. PLoS One 11 (1), e01465105

    Not in our library10.1371/journal.pone.0146510

  131. 131.

    Schwebke J. R. Desmond R. A. (2007 ). A Randomized Trial of the Duration of Therapy With Metronidazole Plus or Minus Azithromycin for Treatment of Symptomatic Bacterial Vaginosis. Clin. Infect. Dis. 44 (2), 213–219

    Not in our library10.1086/509577

  132. 132.

    Schwebke J. R. Lensing S. Y. Lee J. Muzny C. A. Pontius A. Woznicki N.. (2021 ). Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin. Infect. Dis. 73 (3), e672–e795

    Not in our library10.1093/cid/ciaa1903

  133. 133.

    Sgibnev A. V. Kremleva E. A. (2015 ). Vaginal Protection by H2O2-Producing Lactobacilli. Jundishapur J. Microbiol. 8 (10), e22913–e22913

    Not in our library10.5812/jjm.22913

  134. 134.

    Sharma H. Tal R. Clark N. A. Segars J. H. (2014 ). Microbiota and Pelvic Inflammatory Disease. in Seminars in Reproductive Medicine (New York: Thieme Medical Publishers), 43–49

    Not in our library10.1055/s-0033-1361822

  135. 135.

    Sherrard J. Wilson J. Donders G. Mendling W. Jensen J. S. (2018 ). 2018 European (IUSTI/WHO) International Union Against Sexually Transmitted Infections (IUSTI) World Health Organisation (WHO) Guideline on the Management of Vaginal Discharge. Int. J. STD AIDS 29 (13), 1258–1725

    Not in our library10.1177/0956462418785451

  136. 136.

    Shipitsyna E. Khusnutdinova T. Budilovskaya O. Krysanova A. Shalepo K. Savicheva A.. (2020 ). Bacterial Vaginosis-Associated Vaginal Microbiota Is an Age-Independent Risk Factor for Chlamydia Trachomatis, Mycoplasma Genitalium and Trichomonas Vaginalis Infections in Low-Risk Women, St. Petersburg, Russia. Eur. J. Clin. Microbiol. Infect. Dis. 39 (7), 1221–1305

    Not in our library10.1007/s10096-020-03831-w

  137. 137.

    Shujatullah F. Khan H. M. Khatoon R. Rabbani T. Malik A. (2010 ). An Evaluation of OSOM BV Blue Test in the Diagnosis of Bacterial Vaginosis. Asian Pac. J. Trop. Med. 3 (7), 574–765

    Not in our library10.1016/s1995-7645(10)60139-3

  138. 138.

    Sobel J. D. (2017 ). “Vaginitis, Vulvitis, Cervicitis and Cutaneous Vulval Lesions,” in Infectious Diseases (St. Louis: Elsevier), 483–491.

    Not in our library

  139. 139.

    Stoyancheva G. Marzotto M. Dellaglio F. Torriani S. (2014 ). Bacteriocin Production and Gene Sequencing Analysis From Vaginal Lactobacillus Strains. Arch. Microbiol. 196 (9), 645–535

    Not in our library10.1007/s00203-014-1003-1

  140. 140.

    Svare J. A. Schmidt H. Hansen B. B. Lose G. (2006 ). Bacterial Vaginosis in a Cohort of Danish Pregnant Women: Prevalence and Relationship With Preterm Delivery, Low Birthweight and Perinatal Infections. BJOG 113 (12), 1419–1255

    Not in our library10.1111/j.1471-0528.2006.01087.x

  141. 141.

    Swidsinski A. Doerffel Y. Loening-Baucke V. Swidsinski S. Verstraelen H. Vaneechoutte M.. (2010 a). Gardnerella Biofilm Involves Females and Males and Is Transmitted Sexually. Gynecol. Obstet. Invest. 70 (4), 256–635

    Not in our library10.1159/000314015

  142. 142.

    Swidsinski A. Dörffel Y. Loening-Baucke V. Mendling W. Verstraelen H. Dieterle S.. (2010 b). Desquamated Epithelial Cells Covered With a Polymicrobial Biofilm Typical for Bacterial Vaginosis Are Present in Randomly Selected Cryopreserved Donor Semen. FEMS Immunol. Med. Microbiol. 59 (3), 399–4045

    Not in our library10.1111/j.1574-695x.2010.00688.x

  143. 143.

    Tachedjian G. Aldunate M. Bradshaw C. S. Cone R. A. (2017 ). The Role of Lactic Acid Production by Probiotic Lactobacillus Species in Vaginal Health. Res. Microbiol. 168 (9–10), 782–792

    Not in our library10.1016/j.resmic.2017.04.001

  144. 144.

    Thulkar J. Kriplani A. Agarwal N. (2012 ). A Comparative Study of Oral Single Dose of Metronidazole, Tinidazole, Secnidazole and Ornidazole in Bacterial Vaginosis. Indian J. Pharmacol. 44 (2), 2435

    Not in our library10.4103/0253-7613.93859

  145. 145.

    Tidbury F. D. Langhart A. Weidlinger S. Stute P. (2020 ). Non-Antibiotic Treatment of Bacterial Vaginosis—a Systematic Review. Arch. Gynecol. Obstet. 303, 1–9

    Not in our library10.1007/s00404-020-05821-x

  146. 146.

    Trabert B. Misra D. P. (2007 ). Risk Factors for Bacterial Vaginosis During Pregnancy Among African American Women. Am. J. Obstet. Gynecol. 197 (5), 477–e15

    Not in our library10.1016/j.ajog.2007.03.085

  147. 147.

    Vaneechoutte M. Guschin A. Van Simaey L. Gansemans Y. Van Nieuwerburgh F. Cools P. (2019 ). Emended Description of Gardnerella Vaginalis and Description of Gardnerella Leopoldii Sp. Nov., Gardnerella Piotii Sp. Nov. And Gardnerella Swidsinskii Sp. Nov., With Delineation of 13 Genomic Species Within the Genus Gardnerella. Int. J. Syst. Evol. Microbiol. 69 (3), 679–687

    Not in our library10.1099/ijsem.0.003200

  148. 148.

    van Oostrum N. De Sutter P. Meys J. Verstraelen H. (2013 ). Risks Associated With Bacterial Vaginosis in Infertility Patients: A Systematic Review and Meta-Analysis. Hum. Reprod. 28 (7), 1809–1155

    Not in our library10.1093/humrep/det096

  149. 149.

    Verstraelen H. Verhelst R. Vaneechoutte M. Temmerman M. (2010 ). The Epidemiology of Bacterial Vaginosis in Relation to Sexual Behaviour. BMC Infect. Dis. 10 (1), 1–115

    Not in our library10.1186/1471-2334-10-81

  150. 150.

    Vicariotto F. Mogna L. Del Piano M. (2014 ). Effectiveness of the Two Microorganisms Lactobacillus Fermentum LF15 and Lactobacillus Plantarum LP01, Formulated in Slow-Release Vaginal Tablets, in Women Affected by Bacterial Vaginosis: A Pilot Study. J. Clin. Gastroenterol. 48, S106–S112

    Not in our library10.1097/mcg.0000000000000226

  151. 151.

    Vujic G. Knez A. J. Despot Stefanovic V. Kuzmic Vrbanovic V. (2013 ). Efficacy of Orally Applied Probiotic Capsules for Bacterial Vaginosis and Other Vaginal Infections: A Double-Blind, Randomized, Placebo-Controlled Study. Eur. J. Obstet. Gynecol. Reprod. Biol. 168 (1), 75–795

    Not in our library10.1016/j.ejogrb.2012.12.031

  152. 152.

    Wang Z. Zhang L. Zhao M. Wang Y. Bai H. Wang Y.. (2020 ). Deep Neural Networks Offer Morphologic Classification and Diagnosis of Bacterial Vaginosis. J. Clin. Microbiol. 59 (2), e02236–20

    Not in our library10.1128/jcm.02236-20

  153. 153.

    Weissenbacher E. R. Donders G. Unzeitig V. Martinez De Tejada B. Gerber S. Halaška M.. (2012 ). A Comparison of Dequalinium Chloride Vaginal Tablets (Fluomizin®) and Clindamycin Vaginal Cream in the Treatment of Bacterial Vaginosis: A Single-Blind, Randomized Clinical Trial of Efficacy and Safety. Gynecol. Obstet. Invest. 73 (1), 8–155

    Not in our library10.1159/000332398

  154. 154.

    Wessels J. M. Lajoie J. Vitali D. Omollo K. Kimani J. Oyugi J.. (2017 ). Association of High-Risk Sexual Behaviour With Diversity of the Vaginal Microbiota and Abundance of Lactobacillus. PLoS One 12 (11), e01876125

    Not in our library10.1371/journal.pone.0187612

  155. 155.

    Wewalka G. Stary A. Bosse B. Duerr H. E. Reimer K. (2002 ). Efficacy of Povidone-Iodine Vaginal Suppositories in the Treatment of Bacterial Vaginosis. Dermatology 204 (Suppl. 1), 79–85

    Not in our library10.1159/000057731

  156. 156.

    Wiesenfeld H. C. Hillier S. L. Krohn M. A. Landers D. V. Sweet R. L. (2003 ). Bacterial Vaginosis Is a Strong Predictor of Neisseria Gonorrhoeae and Chlamydia Trachomatis Infection. Clin. Infect. Dis. 36 (5), 663–685

    Not in our library10.1086/367658

  157. 157.

    Wilson B. A. Thomas S. M. Ho M. (2011 ). “The Human Vaginal Microbiome,” in Metagenomics of the Human Body (New York: Springer), 91–115.

    Not in our library

  158. 158.

    Witkin S. S. (2015 ). The Vaginal Microbiome, Vaginal Anti-Microbial Defence Mechanisms and the Clinical Challenge of Reducing Infection-Related Preterm Birth. BJOG 122 (2), 213–218

    Not in our library10.1111/1471-0528.13115

  159. 159.

    World Health Organization (2021 ). Guidelines for the Management of Symptomatic Sexually Transmitted Infections. (Geneva, Switerzerland: World Health Organization).

    Not in our library

  160. 160.
    Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis · 2016
    No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.